Shire is a supporter of Canada's Access to Medicines Regime (CAMR) -- under which Canadian generic companies can manufacture in Canada a fixed dose triple combination antiretroviral medicine that contains 3TC(R), a patented drug over which Shire Canada owns the local patent rights. According to Shire Canada VC Claude Perron,
"Shire is totally supportive of this initiative, and will work collaboratively with government and non-governmental agencies worldwide to help secure medicines for those that request it. Our industry wide efforts are aimed not only at preventing and treating HIV/AIDS but also tuberculosis, malaria and other diseases that affect sub Saharan Africa."The CAMR is a positive consequence of the August 2003 World Trade Organization (WTO) agreement which lets WTO member countries with pharmaceutical manufacturing capacity issue licences for the manufacture and export of generic versions of patented drugs and medical devices to developing countries that do not have the capacity to manufacture the products themselves.